Literature DB >> 9541170

Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozotocin-diabetic rats.

P Fernyhough1, L T Diemel, D R Tomlinson.   

Abstract

Neurotrophin-3 (NT-3) acts as a target-derived neurotrophic factor for large calibre sensory neurones and plays a role in the maintenance of the adult phenotype of proprioceptive and mechanoreceptive fibres. Large fibre sensory neuropathy is common in diabetes mellitus and the aim of this study was to determine whether endogenous NT-3-dependent neurotrophic support was sub-optimal in the streptozotocin-diabetic rat. NT-3 gene expression was analysed by Northern blotting and ELISA in hindlimb skeletal muscle and found to be decreased by up to 70% (p < 0.05) in rats with 4-6 weeks of diabetes compared to aged-matched controls. Treatment of other diabetic rats with insulin prevented development of deficits of both NT-3 protein and of its mRNA. The deficits in target tissue production of NT-3 were coincident with significant decreases in its anterograde and retrograde axonal transport in sciatic nerve at 6 weeks of diabetes. The mRNA expression in lumbar dorsal root ganglia of the specific receptor for NT-3, trkC, was also down-regulated at 12 weeks of diabetes by 50% (p < 0.05). The observed decreases in NT-3 target tissue production and related axonal transport suggest that large calibre sensory neurones expressing trkC may be receiving sub-optimal neurotrophic support in experimental diabetes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541170     DOI: 10.1007/s001250050907

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice.

Authors:  J A Christianson; J M Ryals; M S Johnson; R T Dobrowsky; D E Wright
Journal:  Neuroscience       Date:  2006-12-16       Impact factor: 3.590

Review 2.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

3.  The other bladder syndrome: underactive bladder.

Authors:  Minoru Miyazato; Naoki Yoshimura; Michael B Chancellor
Journal:  Rev Urol       Date:  2013

Review 4.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

5.  Neuronal nitric oxide synthase mRNA upregulation in rat sensory neurons after spinal nerve ligation: lack of a role in allodynia development.

Authors:  Z D Luo; S R Chaplan; B P Scott; D Cizkova; N A Calcutt; T L Yaksh
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

6.  Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy.

Authors:  R E Schmidt; D A Dorsey; L N Beaudet; S B Plurad; C A Parvin; M S Miller
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 7.  Presence and Risk Factors for Glaucoma in Patients with Diabetes.

Authors:  Brian J Song; Lloyd Paul Aiello; Louis R Pasquale
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

8.  The p75 neurotrophin receptor appears in plasma in diabetic rats-characterisation of a potential early test for neuropathy.

Authors:  L Chilton; A Middlemas; N Gardiner; D R Tomlinson
Journal:  Diabetologia       Date:  2004-11-19       Impact factor: 10.122

9.  The role of the p75 neurotrophin receptor in the morphology of dorsal root ganglion cells in streptozotocin diabetic mice: effects of sciatic nerve crush.

Authors:  Y Jiang; J Jakobsen
Journal:  Diabetologia       Date:  2004-09-09       Impact factor: 10.122

10.  Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer.

Authors:  M Chattopadhyay; M Mata; J Goss; D Wolfe; S Huang; J C Glorioso; D J Fink
Journal:  Diabetologia       Date:  2007-05-17       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.